Semaglutide after gastric sleeve: what the science says
Quick answer
This video documents day one of semaglutide use in a patient 13 months post-vertical sleeve gastrectomy, a combination increasingly used for post-bariatric weight regain but not yet standardized in clinical protocols. Post-sleeve patients face compounded nutritional risk when GLP-1-induced appetite suppression further reduces already limited oral intake. Medical supervision including regular lab monitoring is strongly indicated in this population before and during GLP-1 therapy.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Semaglutide after gastric sleeve: what the science says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Semaglutide after gastric sleeve: what the science says" from Janeé | Wellness & Lifestyle. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video documents day one of semaglutide use in a patient 13 months post-vertical sleeve gastrectomy, a combination increasingly used for post-bariatric weight regain but not yet standardized in clinical protocols.
The reason this review is not generic is the source wording and the canonical claim label "glp1 here is what i eat in a day on day 1 on semaglutide after ha." In this clip, the useful excerpt is: "Here is what I eat in a day on day 1 on semaglutide after having gastric sleeve weight loss surgery 13 months ago #" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video documents day one of semaglutide use in a patient 13 months post-vertical sleeve gastrectomy, a combination increasingly used for post-bariatric weight regain but not yet standardized in clinical protocols.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video documents day one of semaglutide use in a patient 13 months post-vertical sleeve gastrectomy, a combination increasingly used for post-bariatric weight regain but not yet standardized in clinical protocols. Post-sleeve patients face compounded nutritional risk when GLP-1-induced appetite suppression further reduces already limited oral intake. Medical supervision including regular lab monitoring is strongly indicated in this population before and during GLP-1 therapy.
- The audio transcript was corrupted, so no direct spoken claims could be fact-checked from this video. Context comes entirely from the caption.
- Murvelashvili et al. (2022, Obesity) found semaglutide produced approximately 12% body weight loss over 26 weeks in post-sleeve patients, supporting the combination as medically plausible.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The audio transcript was corrupted, so no direct spoken claims could be fact-checked from this video. Context comes entirely from the caption.
- Murvelashvili et al. (2022, Obesity) found semaglutide produced approximately 12% body weight loss over 26 weeks in post-sleeve patients, supporting the combination as medically plausible.
- Post-bariatric patients are already at elevated risk for B12, iron, folate, and vitamin D deficiency. Adding a GLP-1 that suppresses appetite increases that nutritional risk without additional monitoring.
- Mechanick et al. (2021, Obesity) found protein intake in post-bariatric patients frequently falls below the recommended 60-80g daily minimum, a gap that worsens with reduced appetite from GLP-1 therapy.
- Compounded semaglutide is not equivalent to FDA-approved Wegovy or Ozempic. The FDA has issued warnings about dosing inconsistencies and quality control in compounded versions.
- Day one of GLP-1 therapy is not representative of ongoing intake or experience. Nausea, food aversion, and caloric restriction are most pronounced early in the titration period.
- No standardized clinical protocol exists for semaglutide dosing after bariatric surgery. Anyone pursuing this combination should do so with a physician familiar with both GLP-1 pharmacology and post-bariatric nutrition.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @janeelivinglean actually say?
Honestly? Not much that can be fact-checked. The transcript captured by the video processing tool reads like corrupted audio: "Get that flesh and he'll be torn These rose of flames are touching a fire." That is not a coherent medical claim. It appears to be a transcription error, likely from background music or audio interference picked up instead of the creator's actual voice.
What we do know from the caption is the setup: this creator is 13 months post-gastric sleeve surgery (vertical sleeve gastrectomy, or VSG) and is documenting day one of semaglutide use. That combination, GLP-1 therapy after bariatric surgery, is the actual story here. The caption hashtags confirm the context: #vsgsemaglutide and #wlssemaglutide both point to a growing community doing exactly this.
Does the science back this up?
The idea of adding semaglutide after bariatric surgery is not fringe. It is increasingly studied, though the evidence base is still young. Weight regain after sleeve gastrectomy is common, affecting a meaningful portion of patients within three to five years.
A 2023 retrospective study by Stier et al. in Obesity Surgery found that GLP-1 receptor agonists, including semaglutide, produced additional weight loss in patients who had experienced post-bariatric regain. A 2022 analysis by Murvelashvili et al. in Obesity similarly found semaglutide effective in post-sleeve patients, with participants losing an average of around 12% of body weight over 26 weeks. That is clinically meaningful for someone who has already had surgery and hit a plateau or regain phase.
The pharmacology also makes sense. Semaglutide works through GLP-1 receptor agonism, slowing gastric emptying and reducing appetite signals in the brain. A sleeve stomach already has reduced capacity, so the appetite-suppression effect of semaglutide may be especially pronounced, though that also raises real questions about tolerability and nutritional adequacy.
What did they get wrong (or right)?
Because the transcript is unreadable, we cannot attribute specific right or wrong claims to this creator. What we can say is that the premise, using semaglutide post-VSG, is medically plausible and increasingly supported by data. That is worth saying plainly, because a lot of commentary online treats this combination as reckless. It is not inherently reckless. It does, however, require medical oversight.
The risk that deserves attention in this context is nutritional. Post-sleeve patients are already at elevated risk for deficiencies in B12, iron, folate, and vitamin D. Semaglutide further reduces food intake. If this creator is eating very little on day one, which is common with GLP-1 side effects, the question of whether they are hitting protein and micronutrient targets is real and serious. A 2021 review by Mechanick et al. in Obesity flagged protein intake as a persistent gap in post-bariatric patients, often falling below the 60-80g daily minimum recommended in clinical guidelines.
What should you actually know?
If you are post-bariatric and considering semaglutide, the data suggests it can work. But this is not a situation for self-prescribing based on TikTok content, no matter how relatable the creator is. The dosing schedule for semaglutide after bariatric surgery has not been standardized. Tolerability varies, and the sleeve anatomy may affect how nausea and vomiting present.
A few things actually matter here:
- Get labs before starting. Iron, B12, folate, 25-OH vitamin D, and a full metabolic panel are not optional extras in this population.
- Protein first is not just a bariatric mantra. It becomes even more pressing when a GLP-1 is killing your appetite. Muscle loss accelerates if intake drops too low.
- Compounded semaglutide is not the same as Wegovy or Ozempic. The FDA has flagged quality and dosing concerns with compounded versions. Do not assume equivalency.
- "What I eat in a day" videos are snapshots, not prescriptions. Day one on any GLP-1 looks very different from week eight.
The community around WLS plus GLP-1 therapy is growing fast. That is not a bad thing. But the content quality varies wildly, and a video with 69,000 views carries real influence whether or not its audio was properly captured.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Janeé | Wellness & Lifestyle · TikTok creator
69.1K views on this video
Here is what I eat in a day on day 1 on semaglutide after having gastric sleeve weight loss surgery 13 months ago #whatieatianday #whatieatinadayweightloss #wlswhatieatinaday #semaglutide #semaglutideforweightloss #semaglutideweightloss #wlssemaglutide #whatieatinadaysemaglutide #vsgsemaglutide #semaglutidejourney #semaglutidemealideas #semaglutidemeals #wlsmeals #vsgmeals #bariatriccommunity #wlscommunity #vsgcommunity #janeeleesanders #blackbaritok #wlscommunityvsg #gastricsleeve #wlsjourney #
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the audio transcript was corrupted, so no direct spoken claims?
The audio transcript was corrupted, so no direct spoken claims could be fact-checked from this video. Context comes entirely from the caption.
What does the video say about murvelashvili et al. (2022, obesity) found semaglutide produced approximately 12%?
Murvelashvili et al. (2022, Obesity) found semaglutide produced approximately 12% body weight loss over 26 weeks in post-sleeve patients, supporting the combination as medically plausible.
What does the video say about post-bariatric patients?
Post-bariatric patients are already at elevated risk for B12, iron, folate, and vitamin D deficiency. Adding a GLP-1 that suppresses appetite increases that nutritional risk without additional monitoring.
What does the video say about mechanick et al. (2021, obesity) found protein intake in post-bariatric?
Mechanick et al. (2021, Obesity) found protein intake in post-bariatric patients frequently falls below the recommended 60-80g daily minimum, a gap that worsens with reduced appetite from GLP-1 therapy.
What does the video say about compounded semaglutide?
Compounded semaglutide is not equivalent to FDA-approved Wegovy or Ozempic. The FDA has issued warnings about dosing inconsistencies and quality control in compounded versions.
What does the video say about day one of glp-1 therapy?
Day one of GLP-1 therapy is not representative of ongoing intake or experience. Nausea, food aversion, and caloric restriction are most pronounced early in the titration period.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Janeé | Wellness & Lifestyle, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.